CBLL vs LNTH vs NEOG Stock Comparison

Ceribell, Lantheus Holdings and Neogen Prices as of Oct 23, 2026 Peers: Industry group
CBLL Ceribell, Inc.
$27.13 +14.9% 1M +109.7% 1Y
Market cap
$1.03B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins
LNTH Lantheus Holdings, Inc.
$99.80 -0.2% 1M +76.6% 1Y
Market cap
$6.51B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
NEOG Neogen Corp
$12.19 -10.2% 1M +100.8% 1Y
Market cap
$2.66B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

10 decided of 12

Lantheus Holdings leads on 8 of the 12 questions below (Lantheus Holdings 8, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCBLLLNTHNEOGLeader
Larger companyMarket capitalisation $1.03B $6.51B $2.66B LNTH
Cheaper on earningsLower P/E, profitable companies only -15.6x 23.7x -47.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 17.3x 39.3x LNTH
Faster revenue growthRevenue growth, trailing twelve months +31.7% +2.3% -0.3% CBLL
More profitableNet margin, trailing twelve months -64.7% 17.7% -6.3% LNTH
Better return on capitalReturn on invested capital — 12.5% -0.2% LNTH
Less leveragedLower net debt / EBITDA 1.6x -0.1x 5.4x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +109.7% +76.6% +100.8% CBLL
Better 5-year returnAnnualised price return, 5 years — +34.5%/yr -21.6%/yr LNTH
Less volatileAnnualised volatility, 1 year 52.1% 32.5% 55.6% LNTH
Higher overall scoreMean of the five percentile scores vs peers 38/100 80/100 57/100 LNTH

Percentile Scorecard

CBLLLNTHNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCBLLLNTHNEOG
Valuation 22 #179 of 228 80 #46 of 228 72 #65 of 228
Growth 20 #177 of 222 62 #84 of 222 48 #115 of 222
Profitability 36 #134 of 210 94 #13 of 210 61 #83 of 210
Financial Health 81 #46 of 241 70 #74 of 241 47 #129 of 241
Shareholder Returns 30 #97 of 138 93 #11 of 138 58 #59 of 138
Overall 38 80 57
  • CBLL ranked among 248 companies in Medical Devices and Diagnostics
  • LNTH ranked among 248 companies in Medical Devices and Diagnostics
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCBLLLNTHNEOGSPY
1 month +14.9%-0.2%-10.2% -1.0%
3 months +60.4%-4.8%+29.7% +2.9%
6 months +28.1%+18.3%+27.8% +6.4%
Year to date +23.7%+50.0%+74.4% +11.4%
1 year +109.7%+76.6%+100.8% +13.1%
3 years —+45.7%-19.8% +79.4%
3 years, per year —+13.4%-7.1% +21.5%
5 years —+339.3%-70.3% +67.7%
5 years, per year —+34.5%-21.6% +10.9%
10 years —+1,002.8%-37.6% +255.2%
10 years, per year —+27.1%-4.6% +13.5%

Risk

MeasureCBLLLNTHNEOGSPY
Volatility, 1Y 52.1%32.5%55.6% 12.7%
Downside volatility, 1Y 49.5%27.5%46.5% 12.7%
Beta vs S&P 500, 1Y 1.200.601.44 1.00
Return / volatility, 1Y 2.102.361.81 1.03
Max drawdown, 5Y -63.9%-59.5%-90.6% -25.4%
From 52-week high -2.0%-10.0%-12.8% -2.5%
52-week high $27.68$110.94$13.98 $779.14
52-week low $10.92$50.69$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCBLLLNTHNEOG
P/E now vs peer median -15.6xmedian 30.7x 23.6xmedian 30.7x -47.4xmedian 30.7x
P/S now vs peer median 10.2xmedian 3.0x 4.2xmedian 3.0x 3.0xmedian 3.0x
EV/EBITDA now vs peer median -13.6xmedian 17.7x 16.4xmedian 17.7x 29.4xmedian 17.7x
P/FCF now vs peer median -19.0xmedian 23.7x 16.8xmedian 23.7x 53.4xmedian 23.7x
P/B now vs peer median 8.1xmedian 2.4x 5.0xmedian 2.4x 1.3xmedian 2.4x
PEG now vs peer median —median 0.96 0.22median 0.96 1.69median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCBLLLNTHNEOG
Revenue $101.96M $1.56B $883.99M
Gross profit $90.65M $936.02M $418.98M
Operating income -$69.97M $302.34M -$7.38M
Net income -$66.00M $275.31M -$56.10M
Free cash flow -$54.72M $387.83M $49.80M
R&D $22.95M $173.09M $19.76M
EPS (diluted) $-1.74 $4.08 $-0.26
Cash & equivalents $32.66M $593.30M $172.00M
Total debt $79.45M $571.05M $3.15B
Shares (diluted) 38.03M 67.52M 218.10M
Enterprise value $429.38M $4.68B $2.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCBLLLNTHNEOG
P/E -15.6x 23.6x -47.4x
P/FCF -19.0x 16.8x 53.4x
P/Operating cash flow -19.2x 15.8x 31.2x
P/S 10.2x 4.2x 3.0x
P/B 8.1x 5.0x 1.3x
P/Tangible book 8.1x 10.5x 3.4x
EV/EBITDA -13.6x 16.4x 29.4x
EV/EBIT -13.3x 21.5x -442.4x
EV/Revenue 9.1x 4.2x 3.7x
EV/FCF -17.0x 16.7x 65.5x
EV/Operating cash flow -17.2x 15.7x 38.3x
PEG (3Y EPS CAGR) – 0.22 1.69

Growth

14 metrics
MetricCBLLLNTHNEOG
Revenue growth (1Y) 31.7% 2.3% -0.3%
Revenue CAGR (3Y) – 11.4% -1.3%
Gross profit growth (1Y) 33.4% -3.4% 1.8%
Gross profit CAGR (3Y) – 16.3% -3.1%
Operating income growth (1Y) -34.6% -30.9% 99.3%
Operating income CAGR (3Y) – 118.8% -29.0%
Net income growth (1Y) -33.6% 1.6% 94.6%
Net income CAGR (3Y) – 102.1% -28.3%
EPS growth (1Y) -27.5% 5.8% 94.6%
EPS CAGR (3Y) – 105.5% -28.0%
Operating cash flow growth (1Y) -44.3% -21.7% -1.9%
Operating cash flow CAGR (3Y) – 14.5% 2.9%
Free cash flow growth (1Y) -41.8% -10.1% 1,631%
Free cash flow CAGR (3Y) – 103.0% 126.1%

Profitability

14 metrics
MetricCBLLLNTHNEOG
Gross margin 88.9% 60.1% 47.4%
EBITDA margin -67.1% 25.4% 12.5%
Operating margin -68.6% 19.4% -0.8%
Pretax margin -64.7% 23.3% -7.7%
Net margin -64.7% 17.7% -6.3%
FCF margin -53.7% 24.9% 5.6%
Operating cash flow margin -53.0% 26.5% 9.6%
Return on equity -49.0% 21.8% -2.7%
Return on assets -38.3% 11.6% -1.7%
Return on invested capital – 12.5% -0.2%
Return on capital employed -45.1% 14.8% -0.2%
Asset turnover 0.6x 0.7x 0.3x
Cash conversion (OCF / net income) 0.8x 1.5x -1.5x
Stock comp / revenue 16.1% 5.0% 1.3%

Financial Health

11 metrics
MetricCBLLLNTHNEOG
Debt / assets 12.0% 23.6% 23.4%
Debt / equity 0.2x 0.4x 0.4x
Net debt / EBITDA 1.6x -0.1x 5.4x
Debt / FCF -0.4x 1.5x 15.5x
Liabilities / assets 22.9% 45.7% 36.8%
Equity / assets 77.1% 54.3% 63.2%
Interest coverage -38.6x 15.3x –
Current ratio 9.2x 3.1x 3.9x
Quick ratio 8.6x 2.8x 2.1x
Cash ratio 7.5x 1.8x 1.2x
Altman Z-score 14.41 5.45 1.49

Shareholder Returns

7 metrics
MetricCBLLLNTHNEOG
Dividend yield – – –
Net buyback yield -0.6% 2.9% -0.1%
Shareholder yield -0.6% 2.9% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCBLLLNTHNEOG
Forward P/E – 17.3xFY2026 39.3xFY2026
EPS, next fiscal year $-1.86FY2026 $5.76FY2026 $0.31FY2026
EPS growth, next FY – -5.3%FY2026 -3.1%FY2026
EPS growth, the year after – +4.2% +25.8%
Revenue, next fiscal year $118.32MFY2026 $1.57BFY2026 $845.87MFY2026
Revenue growth, next FY +32.9%FY2026 +1.8%FY2026 -2.8%FY2026
Revenue growth, the year after +21.1% +12.7% +1.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCBLLLNTHNEOG
Held by institutions 79.9% 100.0% 100.0%
Institutions holding 124 465 315
Change in shares held, QoQ +2.2% +3.4% +1.6%
Institutions buying 74 248 151
Institutions selling 36 142 106
Buyers to sellers 2.06 1.75 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CBLLLNTHNEOG
CBLL 1.00 0.21 0.25
LNTH 0.21 1.00 0.08
NEOG 0.25 0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CBLL, LNTH and NEOG?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Ceribell (CBLL) $1.03B, Lantheus Holdings (LNTH) $6.51B, Neogen (NEOG) $2.66B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Ceribell (CBLL) +31.7%, Lantheus Holdings (LNTH) +2.3%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Ceribell (CBLL) -64.7%, Lantheus Holdings (LNTH) 17.7%, Neogen (NEOG) -6.3%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Ceribell (CBLL) +109.7%, Lantheus Holdings (LNTH) +76.6%, Neogen (NEOG) +100.8%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Lantheus Holdings (LNTH) +34.5%/yr, Neogen (NEOG) -21.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Ceribell (CBLL) 52.1%, Lantheus Holdings (LNTH) 32.5%, Neogen (NEOG) 55.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CBLL, LNTH and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.